Brain research · 2025
Suanzaoren decoction improving chronic insomnia with little effects on functional connectivity within the sensorimotor network.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yao Ping, Guo Zhiguo, Han Yiding, Yan Haohao, Lin Wuhong, Han Ziliang, Liu Min, Chen Min, Li Jie, Guo Xingyan, Cui Long-Biao, Guo Wenbin, Lv Dongsheng
Аннотация
PURPOSE: This study aimed to investigate the sensorimotor network (SMN) alterations in chronic insomnia disorder (CID) following treatment with Suanzaoren decoction (SZRD) or estazolam, and to explore their associations with clinical variables and genetic variations.
PATIENTS AND METHODS: SMN functional connectivity (FC), effective connectivity (EC) and transcription-neuroimaging association analyses were conducted in 82 CID patients and 54 healthy controls (HCs). CID patients received either Suanzaoren decoction (SZRD), or estazolam treatment for six weeks. Subsequently, transcriptome-neuroimaging correlation analysis utilizing the Allen Human Brain Atlas was performed to identify gene profiles and neurotransmitter distributions linked to changes in FC/EC values.
RESULTS: SZRD treatment effectively improved sleep quality. Significant differences were found in the FC and EC of SMN in patients with CID compared with HCs at baseline. The FC and EC values in the CID were associated with multiple neurotransmitter systems, including dopaminergic (DAT), cholinergic (VAChT, α4β2), and glutamatergic (NMDA) systems. Patients showed altered EC from the right fusiform gyrus to the left lateral SMN after estazolam treatment. Furthermore, we identified genes associated with FC and EC in CID, which were enriched in biological processes such as synaptic and ion transmission.
CONCLUSION: Our findings indicate that CID patients exhibit abnormal SMN-related intrinsic function and associated biological correlates. Aberrant SMN activity is a distinctive neuroimaging feature of CID. While estazolam affects SMN activity, SZRD has little influence on SMN-related alterations.
PATIENTS AND METHODS: SMN functional connectivity (FC), effective connectivity (EC) and transcription-neuroimaging association analyses were conducted in 82 CID patients and 54 healthy controls (HCs). CID patients received either Suanzaoren decoction (SZRD), or estazolam treatment for six weeks. Subsequently, transcriptome-neuroimaging correlation analysis utilizing the Allen Human Brain Atlas was performed to identify gene profiles and neurotransmitter distributions linked to changes in FC/EC values.
RESULTS: SZRD treatment effectively improved sleep quality. Significant differences were found in the FC and EC of SMN in patients with CID compared with HCs at baseline. The FC and EC values in the CID were associated with multiple neurotransmitter systems, including dopaminergic (DAT), cholinergic (VAChT, α4β2), and glutamatergic (NMDA) systems. Patients showed altered EC from the right fusiform gyrus to the left lateral SMN after estazolam treatment. Furthermore, we identified genes associated with FC and EC in CID, which were enriched in biological processes such as synaptic and ion transmission.
CONCLUSION: Our findings indicate that CID patients exhibit abnormal SMN-related intrinsic function and associated biological correlates. Aberrant SMN activity is a distinctive neuroimaging feature of CID. While estazolam affects SMN activity, SZRD has little influence on SMN-related alterations.